In a filing, Sagimet Biosciences Inc revealed its President & CEO Happel David acquired Company’s shares for reported $63731.0 on Mar 26 ’24. In the deal valued at $5.27 per share,12,100 shares were bought. As a result of this transaction, Happel David now holds 639,200 shares worth roughly $2.76 million.
Then, Happel David bought 1,600 shares, generating $6,560 in total proceeds. Upon buying the shares at $4.10, the President & CEO now owns 627,100 shares.
Before that, Happel David bought 590 shares. Sagimet Biosciences Inc shares valued at $1,386 were divested by the President & CEO at a price of $2.35 per share. As a result of the transaction, Happel David now holds 590 shares, worth roughly $2548.8.
H.C. Wainwright initiated its Sagimet Biosciences Inc [SGMT] rating to a Buy in a research note published on May 02, 2024; the price target was $32. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in late March with a ‘”an Outperform”‘ rating. TD Cowen began covering SGMT with “an Outperform” recommendation on August 08, 2023. Piper Sandler started covering the stock on August 08, 2023. It rated SGMT as “an Overweight”.
Price Performance Review of SGMT
On Friday, Sagimet Biosciences Inc [NASDAQ:SGMT] saw its stock fall -2.92% to $4.32. Over the last five days, the stock has gained 6.40%. Sagimet Biosciences Inc shares have fallen nearly -20.30% since the year began. SMA at 50 days reached $5.06, while 200 days put it at $7.59. A total of 0.77 million shares were traded, compared to the trading of 1.13 million shares in the previous session.
Levels Of Support And Resistance For SGMT Stock
The 24-hour chart illustrates a support level at 4.13, which if violated will result in even more drops to 3.93. On the upside, there is a resistance level at 4.64. A further resistance level may holdings at 4.95. The Relative Strength Index (RSI) on the 14-day chart is 45.56, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.17, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 56.25%. Stochastics %K at 40.00% indicates the stock is a holding.
The most recent change occurred on August 08, 2023 when JMP Securities began covering the stock and recommended ‘”a Mkt outperform”‘ rating along with a $30 price target.
